On June 22, 2026, Mitacs Accelerate awarded support for a research collaboration between 3C Therapeutics and Professor David Perrin’s laboratory at the University of British Columbia.
On November 14, 2025, a U.S. provisional patent application was filed seeking protection for the TriCore platform and its use in degrader-antibody conjugates.
On October 9, 2025, Mitacs Accelerate awarded support for a research collaboration between 3C Therapeutics and Professor David Perrin’s laboratory at the University of British Columbia.
On July 15, 2025, 3C Therapeutics was approved for financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop and characterize degrader-antibody conjugates using its TriCore platform.
Under an agreement dated April 29, 2025, 3C Therapeutics holds an exclusive, worldwide license from the University of British Columbia and iProgen Biotech Inc. to develop and commercialize the technology underlying its TriCore platform.